WO2007085840A1 - Emulsion - Google Patents

Emulsion Download PDF

Info

Publication number
WO2007085840A1
WO2007085840A1 PCT/GB2007/000261 GB2007000261W WO2007085840A1 WO 2007085840 A1 WO2007085840 A1 WO 2007085840A1 GB 2007000261 W GB2007000261 W GB 2007000261W WO 2007085840 A1 WO2007085840 A1 WO 2007085840A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
composition
emulsion
aqueous phase
solution
Prior art date
Application number
PCT/GB2007/000261
Other languages
French (fr)
Inventor
Ingrild Haug
Kurt Ingvar Draget
Original Assignee
Probio Nutraceuticals As
Cockbain, Julian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36060835&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007085840(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2007209133A priority Critical patent/AU2007209133B2/en
Priority to DK07705032.6T priority patent/DK1978929T3/en
Priority to ES07705032.6T priority patent/ES2609086T3/en
Priority to US12/162,339 priority patent/US9539205B2/en
Priority to JP2008551874A priority patent/JP5339920B2/en
Priority to CN200780006284.3A priority patent/CN101389310B/en
Priority to CA2640069A priority patent/CA2640069C/en
Priority to EP16171445.6A priority patent/EP3090729B1/en
Priority to EA200801602A priority patent/EA014337B1/en
Priority to EP07705032.6A priority patent/EP1978929B1/en
Application filed by Probio Nutraceuticals As, Cockbain, Julian filed Critical Probio Nutraceuticals As
Publication of WO2007085840A1 publication Critical patent/WO2007085840A1/en
Priority to NO20083340A priority patent/NO342508B1/en
Priority to US15/363,372 priority patent/US10383818B2/en
Priority to HRP20161720TT priority patent/HRP20161720T1/en
Priority to NO20180631A priority patent/NO345300B1/en
Priority to US16/436,695 priority patent/US11123288B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G4/00—Chewing gum
    • A23G4/06—Chewing gum characterised by the composition containing organic or inorganic compounds
    • A23G4/066—Chewing gum characterised by the composition containing organic or inorganic compounds characterised by the fat used
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/275—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of animal origin, e.g. chitin
    • A23L29/281—Proteins, e.g. gelatin or collagen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes, or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/325—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil
    • B65D75/327—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil and forming several compartments
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • This invention relates to compositions for oral administration in the form of chewable emulsions containing physiologically tolerable unsaturated fatty acid ester oils.
  • unsaturated fatty acid ester oil is used herein to relate to acyl glycerides and phospholipids, i.e. compounds comprising an unsaturated fatty acid side chain linked by an ester group to an "alcohol” (e.g. polyol) residue.
  • Such compounds are important dietary sources of fatty acids, in particular polyunsaturated fatty acids (PUFAs) and more especially the essential fatty acids. They may also serve as sources for dietary replacements of essential fatty acids, e.g. of conjugated linoleic acid (CLA) which may be used in a weight reduction diet.
  • PUFAs polyunsaturated fatty acids
  • CLA conjugated linoleic acid
  • Particularly important essential fatty acids include the ⁇ -3, ⁇ -6 and ⁇ -9 acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).
  • Other fatty acids commonly used in nutraceuticals and pharmaceuticals include arachidonic acid (AA), alpha linolenic acid (ALA), conjugated linolenic acid (CLN), dihomo-gamma linolenic acid (DGLA) and gamma linolenic acid (GLA).
  • AA arachidonic acid
  • ALA alpha linolenic acid
  • CLN conjugated linolenic acid
  • DGLA dihomo-gamma linolenic acid
  • GLA gamma linolenic acid
  • Such fatty acids typically will contain 12 to 26 carbons, more typically 16 to 22 carbons, and will have a saturated or mono- or poly-ethylenically-unsaturated hydro
  • Typical dietary sources of such fatty acid ester oils include lipids such as animal, fish, plant or microorganism triglycerides and phospholipids, especially the triglycerides.
  • Mono or diglycerides can equally be used as can other esters, e.g. lower alkyl (e.g. Ci -6 alkyl, for example ethyl) esters as well as free fatty acids or physiologically acceptable salts thereof and fatty acid ester waxes.
  • Particularly important sources are fish oils, in particular oily fish oils such as cod-liver oil, halibut-liver oil, etc. as these are rich in ⁇ -3, ⁇ -6 and ⁇ -9 fatty acids.
  • fatty acid ester oils tend to be administered in capsule form, containing liquid oil within a soft gel casing.
  • Such capsule casings are usually made from mammalian gelatin, typically of porcine or bovine origin.
  • the capsules tend to be rather large, sufficiently large indeed to cause problems swallowing them for the young and the elderly.
  • ingestion often involves the capsule being chewed and bursting in the mouth releasing the unpleasantly tasting oil contents.
  • the invention provides an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.
  • composition is in a form which can be broken or fragmented by chewing.
  • the chewable compositions of the invention may be pharmaceuticals, but preferably are nutraceuticals.
  • the oil phase of the emulsion will typically comprise a physiologically tolerable unsaturated fatty acid ester oil as described above, especially an acyl glyceride or a fatty acid ethyl ester, and in particular a fish or plant triglyceride. More preferably, it contains a fish oil. Besides such oils, or mixtures thereof, the oil phase may also if desired contain physiologically tolerable lipid soluble materials, e.g. vitamins, antioxidants, flavourings, colours and other physiologically active materials. If desired, the oil phase may be constituted in whole or part by a phospholipid, in particular a marine (eg pelagic fish or shellfish, for example krill) phospholipid.
  • a physiologically tolerable unsaturated fatty acid ester oil as described above, especially an acyl glyceride or a fatty acid ethyl ester, and in particular a fish or plant triglyceride. More preferably, it contains a fish oil.
  • the oil phase preferably contains 25 to 100% of the recommended daily dosage for one or more essential fatty acids, especially EPA and/or DHA.
  • the oil phase will constitute 0.05 to 5g, preferably 0.1 to 3g, especially 0.2 to 2g, particularly 0.3 to 1.25g, more particularly 0.4 to 0.75g, per dose unit.
  • the oil phase preferably constitutes 5 to 75% wt, especially 30 to 50%wt, eg 40 to 50 % wt. of the dose unit.
  • the aqueous phase of the emulsion comprises water and a physiologically tolerable gelling agent, preferably a saccharide (e.g. an oligosaccharide or polysaccharide), a protein or a glycoprotein.
  • a physiologically tolerable gelling agent preferably a saccharide (e.g. an oligosaccharide or polysaccharide), a protein or a glycoprotein.
  • Suitable gelling agents are well known in the food, pharmaceutical and nutraceutical industries and several are described for example in Phillips et al. (Ed.) "Handbook of hydrocolloids", Woodhead Publishing, Cambridge, UK, 2000.
  • the gelling agents are preferably materials capable of undergoing a sol-gel transformation, e.g. under the influence of a change in physiochemical parameters such as temperature, pH, presence of metal ions (e.g. group 1 or 2 metal ions), etc.
  • Preferred for use as the gelling agent is gelatin or a mixture of gelatin and a polysaccharide, or gellan, or an alginate (eg sodium alginate), or a mixture of an alginate and glucono-delta-lactone (GDL).
  • the use offish gelatins is especially preferred.
  • the gelatins used as gelling agents in the composition of the invention may be produced from the collagen of any mammal or the collagen of any aquatic species, however the use of gelatin from salt-water fish and in particular cold water fish is preferred. Gelatins having an imino acid content of 5 to 25% wt. are preferred, more especially those having an imino acid content of 10 to 25% wt.
  • the gelatins will typically have a weight average molecular weight in the range 10 to 250 kDa, preferably 75 to 220 kDa, especially 80 to 200 kDa. Gelatins having Bloom values of 60-300, especially 90-200 are preferred.
  • the gelatin will typically be present in the aqueous phase at a concentration of 1 to 50% wt., preferably 2 to 35% wt., particularly 5 to 25% wt.
  • the weight ratio of gelatin to polysaccharide in the aqueous phase will. typically be 50:1 to 5:1, preferably 40:1 to 9:1, especially 20:1 to 10:1.
  • polysaccharides or mixtures of polysaccharides and gelatin are used as the gelling agent
  • natural polysaccharides synthetic polysaccharides or semisynthetic polysaccharides, e.g. polysaccharides from plants, fish, terrestrial mammals, algae, bacteria and derivatives and fragmentation products thereof.
  • Typical marine polysaccharides include carageenans, alginates, agars and chitosans.
  • Typical plant polysaccharides include pectins.
  • Typical microorganism polysaccharides include gellans and scleroglucans. The use of charged, e.g.
  • electrostatically charged and/or sulphated polysaccharides is preferred, as is the use of marine polysaccharides, in particular carageenans, and alginates, especially carageenans.
  • Carageenans are used below as representative polysaccharide gelling agents.
  • the carageenan family which includes iota- and kappa-carageenans, is a family of linear sulphated polysaccharides produced from red algae.
  • the repeating disaccharide unit in kappa-carrageenan is ⁇ -D-galactose-4-sulphate and 3,6- anhydro- ⁇ -D-galactose, while that in iota-carrageenan is ⁇ -D-galactose-4-sulphate and 3,6-anhydro- ⁇ -D-galactose-2-sulphate.
  • Both kappa-and iota-carrageenans are used in food preparations.
  • the carrageenans are used as stabilisers, emulsiflers, gelling agents and fat replacers.
  • Both iota and kappa carrageenans form salt- or cold-setting reversible gels in an aqueous environment. Coil-helix transition and aggregation of helices form the gel network. Kappa-carrageenan has binding sites for specific monovalent cations, resulting in gel formation with decreasing shear and elastic moduli in the order Cs + > K + » Na + > Li + . As a rule, an increasing salt concentration enhances the elastic modulus and the setting and melting temperatures of a kappa-carrageenan gel.
  • water-soluble potassium, rubidium, or cesium compounds, particularly potassium compounds, and particularly naturally occurring compounds e.g.
  • salts is preferred when kappa-carrageenan is used according to the invention, e.g. at concentrations of up to 100 mM, more especially up to 50 mM.
  • a salt-dependent conformational transition is also found for iota-carrageenan.
  • the molecules are also known to undergo coil-helix transition with strong helix-stabilisation in the presence of multivalent cations, like Ca 2+ .
  • the use of water-soluble calcium, strontium, barium, iron or aluminium compounds, especially calcium compounds, and particularly naturally occurring compounds (e.g. salts) is preferred when iota- carrageenan is used according to the invention, e.g. at concentrations of up to 100 mM.
  • the polysaccharide gelling agents used according to the invention will typically have weight average molecular weights of 5kDa to 2MDa, preferably 1OkDa to IMDa, most preferably 10OkDa to 90OkDa, particularly 400 to 80OkDa. They will typically be used at concentrations of 0.01 to 5% wt, preferably 0.1 to 1.5 % wt., particularly 0.2 to 1% wt in the aqueous phase. Where mono or multivalent cations, typically group 1 or group 2 metal ions, are included in the aqueous phase, this will typically be at concentrations in the range 2.5 to 100 mM, particularly 5 to 5OmM.
  • emulsiflers emulsion stabilizers
  • pH modifiers emulsion modifiers
  • viscosity modifiers e.g., sweeteners, fillers
  • vitamins e.g. vitamin C, thiamine, riboflavin, niacin, vitamin B6, vitamin B 12, folacin, panthotenic acid
  • minerals e.g., a lipophilic antioxidant, e.g. vitamin E
  • vitamins which may be present in the oil phase are vitamin A, vitamin D and vitamin K.
  • Such further components are used widely in the food, pharmaceutical and nutraceutical industries.
  • cellulose derivatives e.g. hydroxy methyl propyl cellulose
  • emulsion stabilizers is especially preferred.
  • the pH of the aqueous phase of the emulsion is preferably in the range 2 to 9, particularly 3 to 7.5.
  • the aqueous phase preferably has a gelling temperature in the range 10 to 30°C, more preferably 15 to 28 0 C, and a melting temperature in the range 20 to 8O 0 C, more preferably 24 to 60 0 C, especially 28 to 50 0 C.
  • a sweetener is included in the aqueous phase, this will typically be selected from natural sweeteners such as sucrose, fructose, glucose, reduced glucose, maltose, xylitol, maltitol, sorbitol, mannitol, lactitol, isomalt, erythritol, polyglycitol, polyglucitol and glycerol and artificial sweeteners such as aspartame, acesulfame-K, neotame, saccharine, sucralose.
  • natural sweeteners such as sucrose, fructose, glucose, reduced glucose, maltose, xylitol, maltitol, sorbitol, mannitol, lactitol, isomalt, erythritol, polyglycitol, polyglucitol and glycerol
  • artificial sweeteners such as aspartame, acesulfam
  • the emulsion preferably has an oil content of 1 to 90% wt, especially 5 to 80% wt, more especially 20 to 75% wt.
  • the emulsion may be dried to reduce the water content, e.g. to 0.01 to 50% wt, preferably 0.1 to 40% wt, especially 0.5 to 30% wt.
  • the aqueous phase even after any drying step, will constitute at least 10% wt., more preferably at least 20% wt., especially at least 30% wt., particularly at least 40% wt. of the emulsion "residue".
  • the emulsion is dried, e.g.
  • the discontinuous nature of the oil phase is maintained even though the water content of the emulsion residue may be extremely low.
  • a dried gelled emulsion it is preferred that it still contains a continuous gel network phase, e.g. as detectable by electron microscopy.
  • physiologically active agents examples include for example analgesics (eg paracetamol and acetyl salicylic acid) and antihistamines.
  • the overall dose unit weight will be 0.25 to 3g, especially 0.5 to 2.5g, more especially 0.75 to 2g.
  • the invention provides a method of treatment of a human by oral administration of an effective amount of an active agent in oil form or dissolved in an oil, the improvement comprising administering said active agent in a chewable emulsion according to the invention.
  • the method may thus typically be a method of treatment of a disease or ailment (eg pain), a method of nutritional supplementation (eg with a triglyceride) or a method of reducing weight.
  • Emulsion formation may be effected by conventional techniques; however emulsification under a non-oxidising gas, eg nitrogen, is preferred. Likewise, the components of the emulsion are preferably degassed before emulsification and handling and packaging of the set emulsion is preferably performed under such a gas.
  • a non-oxidising gas eg nitrogen
  • the dose units of the emulsion maybe formed for example by moulding, extrusion or cutting or the like.
  • the dose units are preferably in tablet or lozenge form; however for child use they may conveniently be presented in child- friendly form, eg geometric shapes such as rods, strips and tubes, or animal, doll, or vehicle shapes, for example the shape of a popular cartoon character.
  • compositions according to the invention contain a citrus flavour (e.g. orange or lemon oil) in order to mask any remaining oil taste on chewing. It is also particularly preferred that the compositions according to the invention contain xylitol, e.g. as 0.5 to 50% wt, preferably 1 to 40% wt, eg 15 to 40%wt, in order to mask both taste and mouth feel. These may be in the aqueous phase or the oil phase (e.g. as a water-in-oil-in water emulsion), or both; however inclusion in the aqueous phase will generally be sufficient.
  • a citrus flavour e.g. orange or lemon oil
  • xylitol e.g. as 0.5 to 50% wt, preferably 1 to 40% wt, eg 15 to 40%wt
  • the dose units of the compositions of the invention are preferably individually packaged in air-tight containers, eg a sealed wrapper or more preferably a blister of a blister pack.
  • the invention provides a package comprising an air-tight compartment containing one dose unit of a composition according to the invention.
  • the packages according to the invention are preferably in the form of blister packs containing at least two dose units, eg 2 to 100, preferably 6 to 30.
  • a blister pack as is well known, usually comprises a plastic sheet base having moulded indentations or trays in which the item to be packed is placed. The pack is normally sealed with a foil, generally metal or a metal/plastic laminate, generally by heating the areas between the indentations or trays.
  • the packages according to the invention are preferably filled under a non- oxidising gas atmosphere (eg nitrogen) or are flushed with such a gas before sealing.
  • a non- oxidising gas atmosphere eg nitrogen
  • Gelatin 10% wt. Sorbitol: 50% wt. Lemon flavour: 0.15% wt. Yellow color: 0.1% wt. Water: 100% wt.
  • the gelatin is added to the water and allowed to swell for 30 min.
  • the gelatin solution is then heated to 60°C under continuous stirring for 45 min.
  • the sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min.
  • the flavour and color are then added while stirring.
  • the solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min.
  • the resultant solution is degassed under vacuum to remove air bubbles. 0.02% wt. lecithin is added to this solution.
  • Marine oil e.g. commercially available fish liver oil
  • 0.15% wt. lemon flavour is mixed with 0.15% wt. lemon flavour.
  • the marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 45- 50 0 C using an ultra turrax.
  • the emulsion is smooth, soft cores are produced by moulding and left to gel for 30 min at 22°C.
  • the cores are dried to reduce the content of water to approximately 15% wt.
  • the emulsion is prepared as in Example 1 and filled into an animal shape mould using a syringe. The shapes are then sealed into a blister pack.
  • the gelatin is added to the water and allowed to swell for 30 min.
  • the gelatin solution is then heated to 6O 0 C under continuous stirring for 45 min.
  • the xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min.
  • the acid, flavour and colour are then added while stirring.
  • the solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min.
  • the resultant solution is degassed under vacuum to remove air bubbles.
  • Marine oil e.g. commercially available fish liver oil
  • 0.15% wt. lemon flavour is mixed with 0.15% wt. lemon flavour.
  • the marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 45- 50°C using an ultra turrax.
  • the emulsion is smooth, soft cores are produced by moulding and left to gel for 60 min at 22°C.
  • the cores are dried to reduce the content of water to approximately 10% wt
  • the gelatin is added to the water and allowed to swell for 30 min.
  • the gelatin solution is then heated to 60°C under continuous stirring for 45 min.
  • the xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min.
  • the acid, flavour and colour are then added while stirring.
  • the solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min.
  • the resultant solution is degassed under vacuum to remove air bubbles.
  • Olive oil e.g. commercially available Ybarra oil
  • Olive oil is mixed with 0.15% wt. lemon flavour.
  • the oil and the aqueous solution are emulsified in a weight ratio of 1 ;2 at 45-5O 0 C using an ultra turrax.
  • the emulsion is smooth, soft cores are produced by moulding and left to gel for 60 min at 22°C.
  • the cores are dried to reduce the content of water to approximately 10% wt.
  • Aqueous phase Aqueous phase:
  • the gelatin is added to the water and allowed to swell for 30 min.
  • the gelatin solution is then heated to 60°C under continuous stirring for 45 min.
  • the xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min.
  • the acid, flavour and colour are then added while stirring.
  • the solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min.
  • the resultant solution is degassed under vacuum to remove air bubbles.
  • Rapeseed oil (Landlord REMA 1000) is mixed with 0.15% wt. lemon flavour.
  • the oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 45-50°C using an ultra turrax.
  • the emulsion is smooth, soft cores are produced by moulding and left to gel for 60 min at 22 0 C.
  • the cores are dried to reduce the content of water to approximately 10% wt.
  • Aqueous phase Aqueous phase:
  • the kappa-carrageenan and fish gelatin is added to the water and allowed to swell for 30 min.
  • the mixture is then heated to 90 0 C under continuous stirring for 45 min.
  • the xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min at 70 0 C.
  • the flavour and colour are then added while stirring.
  • the solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min.
  • the resultant solution is degassed under vacuum to remove air bubbles.
  • Marine oil e.g. commercially available fish liver oil
  • 0.15% wt. lemon flavour is mixed with 0.15% wt. lemon flavour.
  • the marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 45- 5O 0 C using an ultra turrax.
  • the emulsion is smooth, soft cores are produced by moulding and left to gel for 12 hours at 4°C.
  • the cores are dried at room temperature to reduce the content of water to approximately 10% wt
  • Example 7 Chewable emulsion
  • Aqueous phase Aqueous phase:
  • the gellan is added to the water and the mixture is then heated to 95°C under continuous stirring for 30 min.
  • the xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min at 7O 0 C.
  • the solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min.
  • the resultant solution is degassed under vacuum to remove air bubbles.
  • Marine oil e.g. commercially available fish liver oil
  • 0.15% wt. lemon flavour is mixed with 0.15% wt. lemon flavour.
  • the marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 6O 0 C using an ultra turrax.
  • the emulsion is smooth CaCl 2 is added to a final concentration of 15 mM and soft cores are produced by moulding and left to gel for 180 min at 4 0 C.
  • the cores are dried at room temperature to reduce the content of water to approximately 10% wt.
  • Example 8 Chewable emulsion
  • Aqueous phase Aqueous phase:
  • the gelatin is added to the water and allowed to swell for 30 min.
  • the gelatin solution is then heated to 60°C under continuous stirring for 45 min.
  • the acid, xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min.
  • the flavour and colour are then added while stirring.
  • the solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min.
  • the resultant solution is degassed under vacuum to remove air bubbles.
  • Olive oil is mixed with 0.15% wt. lemon flavour.
  • the olive oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 60°C using an ultra turrax.
  • Aqueous phase Aqueous phase:
  • Na-alginate 0.5%wt Xylitol: 36%wt Sorbitol: 14% wt. Lemon flavour: 0.15% wt. Yellow colour: 0.1% wt. Water: to 100% wt.
  • the alginate is added to the water and dissolved under continuous stirring at room temperature for 6 hours.
  • the xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min at 7O 0 C.
  • the solution is cooled to room temperature and flavour and colour is added.
  • the resultant solution is degassed under vacuum to remove air bubbles.
  • Marine oil e.g. commercially available fish liver oil
  • 0.15% wt. lemon flavour is mixed with 0.15% wt. lemon flavour.
  • the marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at room temperature using an ultra turrax.
  • the emulsion is smooth the CaCO 3 and GDL powders are added (one by one) and mixed into the emulsion by the ultra turrax.
  • Soft cores are produced by moulding and left to gel for 24 hours at room temperature. The cores are dried at room temperature to reduce the content of water to approximately 10% wt Example 10 Chewable emulsion
  • Aqueous phase Aqueous phase:
  • Na-alginate 0.5%wt Xylitol: 36%wt Sorbitol: 14% wt. Lemon flavour: 0.15% wt. Yellow colour: 0.1% wt. Water: to 100% wt.
  • the alginate is added to the water and dissolved under continuous stirring at room temperature for 6 hours.
  • the xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min at 7O 0 C.
  • the solution is cooled to room temperature and flavour and colour is added.
  • the resultant solution is degassed under vacuum to remove air bubbles.
  • Marine oil e.g. commercially available fish liver oil
  • 0.15% wt. lemon flavour is mixed with 0.15% wt. lemon flavour.
  • the marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at room temperature using an ultra turrax.
  • the emulsion is smooth the CaSO 4 and tetrasodiumpyrophosphate powders are added (one by one) and mixed into the emulsion by the ultra turrax.
  • Soft cores are produced by moulding and left to gel for 24 hours at room temperature. The cores are dried at room temperature to reduce the content of water to approximately 10% wt.
  • Example 11 Chewable emulsion
  • Vitamin C ascorbic acid: 1O g
  • the gelatin is added to the water and allowed to swell for 30 min.
  • the gelatin solution is then heated to 70°C under continuous stirring for 45 min.
  • the xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min.
  • the acid, flavour and colour are then added while stirring.
  • the temperature is lowered to 5O 0 C and the vitamin C powder is added to the solution.
  • the solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min.
  • Marine oil e.g. commercially available fish liver oil
  • 0.15% wt. lemon flavour is mixed with 0.15% wt. lemon flavour.
  • the marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 40- 45 0 C using an ultra turrax.
  • the resultant emulsion is degassed under vacuum to remove air bubbles.
  • soft cores are produced by moulding and left to gel for 60 min at 22°C.
  • the cores are dried to reduce the content of water to approximately 10% wt.
  • the emulsion cores of Examples 1, 2 and 4 to 11 are filled into plastic blister pack trays over which a plastic/metal foil laminate is heat sealed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Composite Materials (AREA)
  • Mechanical Engineering (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.

Description

Emulsion
This invention relates to compositions for oral administration in the form of chewable emulsions containing physiologically tolerable unsaturated fatty acid ester oils.
The term unsaturated fatty acid ester oil is used herein to relate to acyl glycerides and phospholipids, i.e. compounds comprising an unsaturated fatty acid side chain linked by an ester group to an "alcohol" (e.g. polyol) residue. Such compounds are important dietary sources of fatty acids, in particular polyunsaturated fatty acids (PUFAs) and more especially the essential fatty acids. They may also serve as sources for dietary replacements of essential fatty acids, e.g. of conjugated linoleic acid (CLA) which may be used in a weight reduction diet. Particularly important essential fatty acids include the ω-3, ω-6 and ω-9 acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Other fatty acids commonly used in nutraceuticals and pharmaceuticals include arachidonic acid (AA), alpha linolenic acid (ALA), conjugated linolenic acid (CLN), dihomo-gamma linolenic acid (DGLA) and gamma linolenic acid (GLA). Such fatty acids typically will contain 12 to 26 carbons, more typically 16 to 22 carbons, and will have a saturated or mono- or poly-ethylenically-unsaturated hydrocarbyl chain.
Typical dietary sources of such fatty acid ester oils include lipids such as animal, fish, plant or microorganism triglycerides and phospholipids, especially the triglycerides. Mono or diglycerides however can equally be used as can other esters, e.g. lower alkyl (e.g. Ci-6 alkyl, for example ethyl) esters as well as free fatty acids or physiologically acceptable salts thereof and fatty acid ester waxes. Particularly important sources are fish oils, in particular oily fish oils such as cod-liver oil, halibut-liver oil, etc. as these are rich in ω-3, ω-6 and ω-9 fatty acids.
However, as anyone who, in childhood, has been on the receiving end of fish oils will recall, the taste, mouthfeel and smell can be vile. In part this is due to the sensitivity to oxidation of the fish oil. As a result fatty acid ester oils tend to be administered in capsule form, containing liquid oil within a soft gel casing. Such capsule casings are usually made from mammalian gelatin, typically of porcine or bovine origin. In order to deliver a reasonable dose of the oil, the capsules tend to be rather large, sufficiently large indeed to cause problems swallowing them for the young and the elderly. As a result, ingestion often involves the capsule being chewed and bursting in the mouth releasing the unpleasantly tasting oil contents.
There is thus a continuing need for improved oral administration forms for unsaturated fatty acid ester oils.
We have now surprisingly found that chewable set emulsions of unsaturated fatty acid esters remain sufficiently free of bad odour and taste.
Thus viewed from one aspect the invention provides an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.
The term "chewable" is used herein in its conventional meaning within the pharmaceutical and nutraceutical industry. That is the composition is in a form which can be broken or fragmented by chewing.
The chewable compositions of the invention may be pharmaceuticals, but preferably are nutraceuticals.
The oil phase of the emulsion will typically comprise a physiologically tolerable unsaturated fatty acid ester oil as described above, especially an acyl glyceride or a fatty acid ethyl ester, and in particular a fish or plant triglyceride. More preferably, it contains a fish oil. Besides such oils, or mixtures thereof, the oil phase may also if desired contain physiologically tolerable lipid soluble materials, e.g. vitamins, antioxidants, flavourings, colours and other physiologically active materials. If desired, the oil phase may be constituted in whole or part by a phospholipid, in particular a marine (eg pelagic fish or shellfish, for example krill) phospholipid. The oil phase preferably contains 25 to 100% of the recommended daily dosage for one or more essential fatty acids, especially EPA and/or DHA. Typically the oil phase will constitute 0.05 to 5g, preferably 0.1 to 3g, especially 0.2 to 2g, particularly 0.3 to 1.25g, more particularly 0.4 to 0.75g, per dose unit. Alternatively put, the oil phase preferably constitutes 5 to 75% wt, especially 30 to 50%wt, eg 40 to 50 % wt. of the dose unit. The aqueous phase of the emulsion comprises water and a physiologically tolerable gelling agent, preferably a saccharide (e.g. an oligosaccharide or polysaccharide), a protein or a glycoprotein. Suitable gelling agents are well known in the food, pharmaceutical and nutraceutical industries and several are described for example in Phillips et al. (Ed.) "Handbook of hydrocolloids", Woodhead Publishing, Cambridge, UK, 2000. The gelling agents are preferably materials capable of undergoing a sol-gel transformation, e.g. under the influence of a change in physiochemical parameters such as temperature, pH, presence of metal ions (e.g. group 1 or 2 metal ions), etc.
Preferred for use as the gelling agent is gelatin or a mixture of gelatin and a polysaccharide, or gellan, or an alginate (eg sodium alginate), or a mixture of an alginate and glucono-delta-lactone (GDL). The use offish gelatins is especially preferred.
The gelatins used as gelling agents in the composition of the invention may be produced from the collagen of any mammal or the collagen of any aquatic species, however the use of gelatin from salt-water fish and in particular cold water fish is preferred. Gelatins having an imino acid content of 5 to 25% wt. are preferred, more especially those having an imino acid content of 10 to 25% wt. The gelatins will typically have a weight average molecular weight in the range 10 to 250 kDa, preferably 75 to 220 kDa, especially 80 to 200 kDa. Gelatins having Bloom values of 60-300, especially 90-200 are preferred. The gelatin will typically be present in the aqueous phase at a concentration of 1 to 50% wt., preferably 2 to 35% wt., particularly 5 to 25% wt. In the case of mixtures of gelatin and polysaccharides, the weight ratio of gelatin to polysaccharide in the aqueous phase will. typically be 50:1 to 5:1, preferably 40:1 to 9:1, especially 20:1 to 10:1.
Where polysaccharides, or mixtures of polysaccharides and gelatin are used as the gelling agent, it is preferred to use natural polysaccharides, synthetic polysaccharides or semisynthetic polysaccharides, e.g. polysaccharides from plants, fish, terrestrial mammals, algae, bacteria and derivatives and fragmentation products thereof. Typical marine polysaccharides include carageenans, alginates, agars and chitosans. Typical plant polysaccharides include pectins. Typical microorganism polysaccharides include gellans and scleroglucans. The use of charged, e.g. electrostatically charged and/or sulphated polysaccharides is preferred, as is the use of marine polysaccharides, in particular carageenans, and alginates, especially carageenans. Carageenans are used below as representative polysaccharide gelling agents.
The carageenan family, which includes iota- and kappa-carageenans, is a family of linear sulphated polysaccharides produced from red algae. The repeating disaccharide unit in kappa-carrageenan is β-D-galactose-4-sulphate and 3,6- anhydro-α-D-galactose, while that in iota-carrageenan is β-D-galactose-4-sulphate and 3,6-anhydro-α-D-galactose-2-sulphate. Both kappa-and iota-carrageenans are used in food preparations. The carrageenans are used as stabilisers, emulsiflers, gelling agents and fat replacers.
Both iota and kappa carrageenans form salt- or cold-setting reversible gels in an aqueous environment. Coil-helix transition and aggregation of helices form the gel network. Kappa-carrageenan has binding sites for specific monovalent cations, resulting in gel formation with decreasing shear and elastic moduli in the order Cs+> K+ » Na+ > Li+. As a rule, an increasing salt concentration enhances the elastic modulus and the setting and melting temperatures of a kappa-carrageenan gel. The use of water-soluble potassium, rubidium, or cesium compounds, particularly potassium compounds, and particularly naturally occurring compounds (e.g. salts) is preferred when kappa-carrageenan is used according to the invention, e.g. at concentrations of up to 100 mM, more especially up to 50 mM. A salt-dependent conformational transition is also found for iota-carrageenan. The molecules are also known to undergo coil-helix transition with strong helix-stabilisation in the presence of multivalent cations, like Ca2+. The use of water-soluble calcium, strontium, barium, iron or aluminium compounds, especially calcium compounds, and particularly naturally occurring compounds (e.g. salts) is preferred when iota- carrageenan is used according to the invention, e.g. at concentrations of up to 100 mM.
The polysaccharide gelling agents used according to the invention will typically have weight average molecular weights of 5kDa to 2MDa, preferably 1OkDa to IMDa, most preferably 10OkDa to 90OkDa, particularly 400 to 80OkDa. They will typically be used at concentrations of 0.01 to 5% wt, preferably 0.1 to 1.5 % wt., particularly 0.2 to 1% wt in the aqueous phase. Where mono or multivalent cations, typically group 1 or group 2 metal ions, are included in the aqueous phase, this will typically be at concentrations in the range 2.5 to 100 mM, particularly 5 to 5OmM.
Besides the gelling agent and water and any required gelling initiator, other physiologically tolerable materials may be present in the aqueous phase, e.g. emulsiflers, emulsion stabilizers, pH modifiers, viscosity modifiers, sweeteners, fillers, vitamins (e.g. vitamin C, thiamine, riboflavin, niacin, vitamin B6, vitamin B 12, folacin, panthotenic acid), minerals, aromas, flavours, colours, physiologically active agents, etc. It is especially preferred that a lipophilic antioxidant, e.g. vitamin E, be included in the oil phase. Other vitamins which may be present in the oil phase are vitamin A, vitamin D and vitamin K. Such further components are used widely in the food, pharmaceutical and nutraceutical industries. The use of cellulose derivatives (e.g. hydroxy methyl propyl cellulose) as emulsion stabilizers is especially preferred.
The pH of the aqueous phase of the emulsion is preferably in the range 2 to 9, particularly 3 to 7.5.
The aqueous phase preferably has a gelling temperature in the range 10 to 30°C, more preferably 15 to 280C, and a melting temperature in the range 20 to 8O0C, more preferably 24 to 600C, especially 28 to 500C.
Where a sweetener is included in the aqueous phase, this will typically be selected from natural sweeteners such as sucrose, fructose, glucose, reduced glucose, maltose, xylitol, maltitol, sorbitol, mannitol, lactitol, isomalt, erythritol, polyglycitol, polyglucitol and glycerol and artificial sweeteners such as aspartame, acesulfame-K, neotame, saccharine, sucralose. The use of non-cariogenic sweeteners is preferred.
The emulsion preferably has an oil content of 1 to 90% wt, especially 5 to 80% wt, more especially 20 to 75% wt. However after emulsification and gelation the emulsion may be dried to reduce the water content, e.g. to 0.01 to 50% wt, preferably 0.1 to 40% wt, especially 0.5 to 30% wt. Particularly preferably however the aqueous phase, even after any drying step, will constitute at least 10% wt., more preferably at least 20% wt., especially at least 30% wt., particularly at least 40% wt. of the emulsion "residue". Where the emulsion is dried, e.g. by lyophilization, the discontinuous nature of the oil phase is maintained even though the water content of the emulsion residue may be extremely low. In general, however, where a dried gelled emulsion is used, it is preferred that it still contains a continuous gel network phase, e.g. as detectable by electron microscopy.
Examples of physiologically active agents that may be included in the capsules of the invention include for example analgesics (eg paracetamol and acetyl salicylic acid) and antihistamines.
Preferably the overall dose unit weight will be 0.25 to 3g, especially 0.5 to 2.5g, more especially 0.75 to 2g.
Viewed from a further aspect the invention provides a method of treatment of a human by oral administration of an effective amount of an active agent in oil form or dissolved in an oil, the improvement comprising administering said active agent in a chewable emulsion according to the invention. The method may thus typically be a method of treatment of a disease or ailment (eg pain), a method of nutritional supplementation (eg with a triglyceride) or a method of reducing weight.
Emulsion formation may be effected by conventional techniques; however emulsification under a non-oxidising gas, eg nitrogen, is preferred. Likewise, the components of the emulsion are preferably degassed before emulsification and handling and packaging of the set emulsion is preferably performed under such a gas.
The dose units of the emulsion maybe formed for example by moulding, extrusion or cutting or the like. For adult use, the dose units are preferably in tablet or lozenge form; however for child use they may conveniently be presented in child- friendly form, eg geometric shapes such as rods, strips and tubes, or animal, doll, or vehicle shapes, for example the shape of a popular cartoon character.
It is particularly preferred that the compositions according to the invention contain a citrus flavour (e.g. orange or lemon oil) in order to mask any remaining oil taste on chewing. It is also particularly preferred that the compositions according to the invention contain xylitol, e.g. as 0.5 to 50% wt, preferably 1 to 40% wt, eg 15 to 40%wt, in order to mask both taste and mouth feel. These may be in the aqueous phase or the oil phase (e.g. as a water-in-oil-in water emulsion), or both; however inclusion in the aqueous phase will generally be sufficient. The dose units of the compositions of the invention are preferably individually packaged in air-tight containers, eg a sealed wrapper or more preferably a blister of a blister pack. Viewed from a further aspect the invention provides a package comprising an air-tight compartment containing one dose unit of a composition according to the invention.
The packages according to the invention are preferably in the form of blister packs containing at least two dose units, eg 2 to 100, preferably 6 to 30. A blister pack, as is well known, usually comprises a plastic sheet base having moulded indentations or trays in which the item to be packed is placed. The pack is normally sealed with a foil, generally metal or a metal/plastic laminate, generally by heating the areas between the indentations or trays.
The packages according to the invention are preferably filled under a non- oxidising gas atmosphere (eg nitrogen) or are flushed with such a gas before sealing.
Of course, in place of unsaturated fatty acid esters, saturated fatty acids and their esters could also be used and this forms a further aspect of the invention.
The invention will now be described further with reference to the following non-limiting Examples.
Example 1 Chewable emulsion
Aqueous phase;
Gelatin: 10% wt. Sorbitol: 50% wt. Lemon flavour: 0.15% wt. Yellow color: 0.1% wt. Water: 100% wt.
The gelatin is added to the water and allowed to swell for 30 min. The gelatin solution is then heated to 60°C under continuous stirring for 45 min. The sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min. The flavour and color are then added while stirring. The solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min. The resultant solution is degassed under vacuum to remove air bubbles. 0.02% wt. lecithin is added to this solution.
Marine oil (e.g. commercially available fish liver oil) is mixed with 0.15% wt. lemon flavour.
The marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 45- 500C using an ultra turrax. When the emulsion is smooth, soft cores are produced by moulding and left to gel for 30 min at 22°C. The cores are dried to reduce the content of water to approximately 15% wt.
Example 2
Chewable emulsion shapes
The emulsion is prepared as in Example 1 and filled into an animal shape mould using a syringe. The shapes are then sealed into a blister pack.
Example 3 Chewable emulsion
Aqueous phase;
Gelatin: 10% wt. Xylitol: 36% wt Sorbitol: 14% wt. Lemon flavour: 0.15% wt. Yellow colour: 0.1% wt. 50% citric acid: 1% wt Water: to 100% wt.
The gelatin is added to the water and allowed to swell for 30 min. The gelatin solution is then heated to 6O0C under continuous stirring for 45 min. The xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min. The acid, flavour and colour are then added while stirring. The solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min. The resultant solution is degassed under vacuum to remove air bubbles.
Marine oil (e.g. commercially available fish liver oil) is mixed with 0.15% wt. lemon flavour.
The marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 45- 50°C using an ultra turrax. When the emulsion is smooth, soft cores are produced by moulding and left to gel for 60 min at 22°C. The cores are dried to reduce the content of water to approximately 10% wt
Example 4 Chewable emulsion
Aqueous phase;
Gelatin: 10% wt. Xylitol: 36% wt Sorbitol: 14% wt. Lemon flavour: 0.15% wt. Yellow colour: 0.1% wt. 50% citric acid: l% wt Water: to 100% wt.
The gelatin is added to the water and allowed to swell for 30 min. The gelatin solution is then heated to 60°C under continuous stirring for 45 min. The xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min. The acid, flavour and colour are then added while stirring. The solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min. The resultant solution is degassed under vacuum to remove air bubbles. Olive oil (e.g. commercially available Ybarra oil) is mixed with 0.15% wt. lemon flavour.
The oil and the aqueous solution are emulsified in a weight ratio of 1 ;2 at 45-5O0C using an ultra turrax. When the emulsion is smooth, soft cores are produced by moulding and left to gel for 60 min at 22°C. The cores are dried to reduce the content of water to approximately 10% wt.
Example 5 Chewable emulsion
Aqueous phase:
Gelatin: 10% wt. Xylitol: 36% wt Sorbitol: 14% wt. Lemon flavour: 0.15% wt. Yellow colour: 0.1% wt. 50% citric acid: l% wt Water: to 100% wt.
The gelatin is added to the water and allowed to swell for 30 min. The gelatin solution is then heated to 60°C under continuous stirring for 45 min. The xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min. The acid, flavour and colour are then added while stirring. The solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min. The resultant solution is degassed under vacuum to remove air bubbles.
Rapeseed oil (Landlord REMA 1000) is mixed with 0.15% wt. lemon flavour.
The oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 45-50°C using an ultra turrax. When the emulsion is smooth, soft cores are produced by moulding and left to gel for 60 min at 220C. The cores are dried to reduce the content of water to approximately 10% wt.
Example 6 Chewable emulsion
Aqueous phase:
Fish gelatin: 10% wt. Kappa-carrageenan: 0.5% wt Xylitol: 36% wt Sorbitol: 14% wt. Lemon flavour: 0.15% wt. Yellow colour: 0.1% wt. Water: to 100% wt.
The kappa-carrageenan and fish gelatin is added to the water and allowed to swell for 30 min. The mixture is then heated to 900C under continuous stirring for 45 min. The xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min at 700C. The flavour and colour are then added while stirring. The solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min. The resultant solution is degassed under vacuum to remove air bubbles.
Marine oil (e.g. commercially available fish liver oil) is mixed with 0.15% wt. lemon flavour.
The marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 45- 5O0C using an ultra turrax. When the emulsion is smooth, soft cores are produced by moulding and left to gel for 12 hours at 4°C. The cores are dried at room temperature to reduce the content of water to approximately 10% wt Example 7 Chewable emulsion
Aqueous phase:
Gellan: 0.5% wt Xylitol: 36% wt Sorbitol: 14% wt. Water: to 100% wt.
CaClrsolution: 15 mM in the water phase
The gellan is added to the water and the mixture is then heated to 95°C under continuous stirring for 30 min. The xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min at 7O0C. The solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min. The resultant solution is degassed under vacuum to remove air bubbles.
Marine oil (e.g. commercially available fish liver oil) is mixed with 0.15% wt. lemon flavour.
The marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 6O0C using an ultra turrax. When the emulsion is smooth CaCl2 is added to a final concentration of 15 mM and soft cores are produced by moulding and left to gel for 180 min at 40C. The cores are dried at room temperature to reduce the content of water to approximately 10% wt. Example 8 Chewable emulsion
Aqueous phase:
Gelatin: 7.5% Xylitol: 36% wt Sorbitol: 14% wt. 50% citric acid: 1% wt Lemon flavour: 0.15% wt. Yellow colour: 0.1% wt. Water: to 100% wt.
Paracetamol: 125 mg/1.5g emulsion
The gelatin is added to the water and allowed to swell for 30 min. The gelatin solution is then heated to 60°C under continuous stirring for 45 min. The acid, xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min. The flavour and colour are then added while stirring. The solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min. The resultant solution is degassed under vacuum to remove air bubbles.
Olive oil is mixed with 0.15% wt. lemon flavour.
The olive oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 60°C using an ultra turrax. "When the emulsion is smooth paracetamol powder is mixed into the emulsion with a ultra turrax and soft cores are produced by moulding and left to gel for 180 min at 2O0C. The cores are dried at room temperature to reduce the content of water to approximately 10% wt. Example 9 Chewable emulsion
Aqueous phase:
Na-alginate: 0.5%wt Xylitol: 36%wt Sorbitol: 14% wt. Lemon flavour: 0.15% wt. Yellow colour: 0.1% wt. Water: to 100% wt.
GDL: 30 niM CaCO3: 15 mM
The alginate is added to the water and dissolved under continuous stirring at room temperature for 6 hours. The xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min at 7O0C. The solution is cooled to room temperature and flavour and colour is added. The resultant solution is degassed under vacuum to remove air bubbles.
Marine oil (e.g. commercially available fish liver oil) is mixed with 0.15% wt. lemon flavour.
The marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at room temperature using an ultra turrax. When the emulsion is smooth the CaCO3 and GDL powders are added (one by one) and mixed into the emulsion by the ultra turrax. Soft cores are produced by moulding and left to gel for 24 hours at room temperature. The cores are dried at room temperature to reduce the content of water to approximately 10% wt Example 10 Chewable emulsion
Aqueous phase:
Na-alginate: 0.5%wt Xylitol: 36%wt Sorbitol: 14% wt. Lemon flavour: 0.15% wt. Yellow colour: 0.1% wt. Water: to 100% wt.
Calsiumsulphate (CaSO4 x 2H2O): 0.3% Tetrasodiumpyrophosphate (Na4P2O7 ): 0.03%
The alginate is added to the water and dissolved under continuous stirring at room temperature for 6 hours. The xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min at 7O0C. The solution is cooled to room temperature and flavour and colour is added. The resultant solution is degassed under vacuum to remove air bubbles.
Marine oil (e.g. commercially available fish liver oil) is mixed with 0.15% wt. lemon flavour.
The marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at room temperature using an ultra turrax. When the emulsion is smooth the CaSO4 and tetrasodiumpyrophosphate powders are added (one by one) and mixed into the emulsion by the ultra turrax. Soft cores are produced by moulding and left to gel for 24 hours at room temperature. The cores are dried at room temperature to reduce the content of water to approximately 10% wt. Example 11 Chewable emulsion
Aqueous phase;
Gelatin: 10% wt. Xylitol: 36% wt Sorbitol: 14% wt. Lemon flavour: 0.15% wt. Yellow colour: 0.1% wt. 50% citric acid: l% wt Water: to 100% wt.
Vitamin C (ascorbic acid): 1O g
The gelatin is added to the water and allowed to swell for 30 min. The gelatin solution is then heated to 70°C under continuous stirring for 45 min. The xylitol and sorbitol is then added to the solution and allowed to dissolve under stirring for 30-60 min. The acid, flavour and colour are then added while stirring. The temperature is lowered to 5O0C and the vitamin C powder is added to the solution. The solution is mixed for 30 min before stirring is stopped and the solution is left for 30 min.
Marine oil (e.g. commercially available fish liver oil) is mixed with 0.15% wt. lemon flavour.
The marine oil and the aqueous solution are emulsified in a weight ratio of 1 :2 at 40- 450C using an ultra turrax. The resultant emulsion is degassed under vacuum to remove air bubbles. When the emulsion is smooth, soft cores are produced by moulding and left to gel for 60 min at 22°C. The cores are dried to reduce the content of water to approximately 10% wt. Example 12 Blister packs
The emulsion cores of Examples 1, 2 and 4 to 11 are filled into plastic blister pack trays over which a plastic/metal foil laminate is heat sealed.
Example 13 Chewable strips
Before setting, the emulsions of Examples 1, 2 and 4 to 12 are extruded into strips which are then sealed into individual plastic/metal foil laminate envelopes.

Claims

Claims:
1. An orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.
2. A composition as claimed in claim 1 wherein the fatty acid ester is a physiologically tolerable triglyceride.
3. A composition as claimed in claim 1 wherein as the fatty acid ester is used a fish oil.
4. A composition as claimed in any one of claims 1 to 3 wherein said aqueous phase comprises a gelling agent selected from gelatin, polysaccharides, and mixtures thereof.
5. A composition as claimed in any one of claims 1 to 3 wherein said aqueous phase comprises gelatin and carageenan.
6. A composition as claimed in any one of claims 1 to 5 containing at least 1% wt. xylitol.
7. A composition as claimed in any one of claims 1 to 6 containing a citrus flavour.
8. A composition as claimed in any one of claims 1 to 7 wherein said aqueous phase comprises a water soluble vitamin.
9. A composition as claimed in any one of the preceding claims in animal, doll, vehicle, rod, strip or tube shape.
10. A package comprising an air-tight compartment containing one dose unit of a composition as claimed in any one of the preceding claims.
11. A package as claimed in claim 10 in the form of a blister pack.
12. A method of treatment of a human by oral administration of an effective amount of an active agent in oil form or dissolved in an oil, the improvement comprising administering said active agent in a chewable composition according to any one of claims 1 to 9.
13. A method as claimed in claim 12 wherein said active agent is an analgesic.
14. A method as claimed in claim 12 wherein said active agent is a triglyceride.
PCT/GB2007/000261 2006-01-25 2007-01-25 Emulsion WO2007085840A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
EP16171445.6A EP3090729B1 (en) 2006-01-25 2007-01-25 Emulsion
EP07705032.6A EP1978929B1 (en) 2006-01-25 2007-01-25 Emulsion
EA200801602A EA014337B1 (en) 2006-01-25 2007-01-25 Chewable composition
US12/162,339 US9539205B2 (en) 2006-01-25 2007-01-25 Emulsion
DK07705032.6T DK1978929T3 (en) 2006-01-25 2007-01-25 EMULSION
CN200780006284.3A CN101389310B (en) 2006-01-25 2007-01-25 Emulsion
CA2640069A CA2640069C (en) 2006-01-25 2007-01-25 Chewable compositions comprising a gelled oil-in-water emulsion
AU2007209133A AU2007209133B2 (en) 2006-01-25 2007-01-25 Emulsion
ES07705032.6T ES2609086T3 (en) 2006-01-25 2007-01-25 Emulsion
JP2008551874A JP5339920B2 (en) 2006-01-25 2007-01-25 emulsion
NO20083340A NO342508B1 (en) 2006-01-25 2008-07-30 emulsion
US15/363,372 US10383818B2 (en) 2006-01-25 2016-11-29 Emulsion
HRP20161720TT HRP20161720T1 (en) 2006-01-25 2016-12-14 Emulsion
NO20180631A NO345300B1 (en) 2006-01-25 2018-05-03 Emulsion
US16/436,695 US11123288B2 (en) 2006-01-25 2019-06-10 Emulsion

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0601498.9 2006-01-25
GBGB0601498.9A GB0601498D0 (en) 2006-01-25 2006-01-25 Product

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/162,339 A-371-Of-International US9539205B2 (en) 2006-01-25 2007-01-25 Emulsion
US15/363,372 Continuation US10383818B2 (en) 2006-01-25 2016-11-29 Emulsion

Publications (1)

Publication Number Publication Date
WO2007085840A1 true WO2007085840A1 (en) 2007-08-02

Family

ID=36060835

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2007/000261 WO2007085840A1 (en) 2006-01-25 2007-01-25 Emulsion
PCT/GB2007/000254 WO2007085835A1 (en) 2006-01-25 2007-01-25 Chewable capsules

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/000254 WO2007085835A1 (en) 2006-01-25 2007-01-25 Chewable capsules

Country Status (15)

Country Link
US (4) US9539205B2 (en)
EP (3) EP1978929B1 (en)
JP (3) JP5339920B2 (en)
CN (3) CN101389310B (en)
AU (2) AU2007209133B2 (en)
CA (2) CA2640529C (en)
DK (1) DK1978929T3 (en)
EA (2) EA019116B1 (en)
ES (3) ES2609086T3 (en)
GB (1) GB0601498D0 (en)
HR (1) HRP20161720T1 (en)
NO (3) NO342489B1 (en)
PL (3) PL3090729T3 (en)
PT (1) PT1978929T (en)
WO (2) WO2007085840A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010041015A2 (en) * 2008-10-08 2010-04-15 Ayanda As Chewable gelled emulsions
WO2010041017A2 (en) * 2008-10-08 2010-04-15 Ayanda As Chewable gelled emulsions
WO2010086235A1 (en) * 2009-01-30 2010-08-05 Unilever Plc Oil-in-water emulsions
WO2011048388A3 (en) * 2009-10-22 2011-06-30 Probio Asa Oral pharmaceutical and nutraceutical compositions
WO2011128635A2 (en) 2010-04-14 2011-10-20 Probio Asa Anti-abuse pharmaceutical compositions
WO2011128627A2 (en) 2010-04-14 2011-10-20 Probio Asa Oral veterinary pharmaceutical and nutraceutical compositions
WO2011128628A2 (en) 2010-04-14 2011-10-20 Probio Asa Gelled oral pharmaceutical compositions
WO2011128632A2 (en) 2010-04-14 2011-10-20 Probio Asa Gelled pharmaceutical composition
WO2011128631A2 (en) 2010-04-14 2011-10-20 Probio Asa Vegetarian oral pharmaceutical and nutraceutical compositions
WO2011128626A1 (en) 2010-04-14 2011-10-20 Probio Asa Essential fatty acid gelled composition
WO2011128633A2 (en) 2010-04-14 2011-10-20 Probio Asa Oral pharmaceutical dispersion compositions
WO2011128629A2 (en) 2010-04-14 2011-10-20 Probio Asa Lipid-vectored drug compositions
WO2011128634A2 (en) 2010-04-14 2011-10-20 Probio Asa Over the counter pharmaceutical compositions
WO2012046066A1 (en) 2010-10-06 2012-04-12 Probio Asa Sour gelled emulsions
WO2011128625A3 (en) * 2010-04-14 2012-05-18 Probio Asa Divisible oral pharmaceutical compositions
WO2012140392A1 (en) 2011-04-11 2012-10-18 Ayanda Group As Oral pharmaceutical dispersion compositions
EP2934422A4 (en) * 2012-12-23 2016-07-20 Vadim Zelikman A gellan gum carrier for a medicament, means and method
US9452135B2 (en) 2012-03-20 2016-09-27 Particle Dynamics International, Llc Gelling agent-based dosage form
WO2017139846A1 (en) * 2016-02-16 2017-08-24 Atp Institute Pty Ltd Formulation and method of use
US10532060B2 (en) 2014-03-03 2020-01-14 Raisio Nutrition Ltd. Serum cholesterol lowering edible product
EP3511010A4 (en) * 2016-09-09 2020-05-13 TCI Co., Ltd. Fish odor-free fish oil composition and preparation method therefor
GB2597773A (en) * 2020-08-05 2022-02-09 Freddy Hirsch Group Ag Upgrade of animal fats
EP3090729B1 (en) 2006-01-25 2023-06-07 Vitux Group AS Emulsion
WO2023161658A1 (en) 2022-02-28 2023-08-31 Vitux Group As Oil-in-water emulsion with agar and diacetyl tartaric acid esters of mono-and di-glycerides (datem)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164217A1 (en) * 2009-09-04 2012-06-28 Dominique Nicolas Cade Scented capsules
JP5875246B2 (en) * 2010-12-10 2016-03-02 日東電工株式会社 Sheet-form preparation and method for producing sheet-form preparation
JP2012176197A (en) * 2011-02-28 2012-09-13 Nagasaki Univ Film echo gel and ultrasonic sensor unit
FI125947B (en) 2013-07-05 2016-04-29 Ravintoraisio Oy Blood cholesterol lowering composition
GB201402450D0 (en) * 2014-02-12 2014-03-26 Aker Biomarine As Liquid phospholipid-containing compositions for preperation of pharmaceuticals
CN106723086A (en) * 2016-11-16 2017-05-31 邓先觉 A kind of medical EA meals and its compound method suitable for children
JP2018115282A (en) * 2017-01-20 2018-07-26 日清オイリオグループ株式会社 Flavor enhancer of citrus flavor and improved flavor
ES2971949T3 (en) * 2017-02-14 2024-06-10 Nestle Sa Preparation method of a dry hydrogel co-gel
US10736276B2 (en) * 2018-07-12 2020-08-11 Agricultural Utilization Research Institute Colloidal barrier materials and methods of making and using the same
CN109984310B (en) * 2019-04-01 2024-02-20 浙江麦尚食品有限公司 Processing method of beef product
CN110478312A (en) * 2019-08-29 2019-11-22 仙乐健康科技股份有限公司 Stable gel composition and its preparation method and application with high fat content
US11707074B2 (en) 2020-04-09 2023-07-25 Kim Schwarz Edible hydration pod and method of manufacturing an edible hydration pod
US12016359B2 (en) 2022-11-11 2024-06-25 Pharmavite Llc Oil-in-water emulsion gummy composition with water soluble active ingredient(s)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764383A (en) * 1985-10-21 1988-08-16 Michael Drebot Soft homogenous fish bait
EP0474261A2 (en) * 1987-11-25 1992-03-11 Meiji Seika Kaisha Ltd. Production of gelatin jelly confections
WO2003053159A1 (en) * 2001-12-20 2003-07-03 Societe Des Produits Nestle S.A. A food product containing gel capsules or tablets
WO2004054539A1 (en) * 2002-12-16 2004-07-01 The Boots Company Plc Medicinal compositions comprising a core and a film based on modified cellulose derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5238954B2 (en) 1975-03-04 1977-10-01
JPS5238954A (en) 1975-09-23 1977-03-25 Mitsutoyo Mfg Co Ltd Cam measuring device
US4389419A (en) * 1980-11-10 1983-06-21 Damon Corporation Vitamin encapsulation
DE3237814A1 (en) * 1982-10-12 1984-04-12 Warner-Lambert Co., 07950 Morris Plains, N.J. WATER-FREE EMULSIONS AND USE THEREOF
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US4961939A (en) * 1989-06-02 1990-10-09 Nabisco Brands, Inc. Deodorized water-in-oil emulsion containing fish oil
JPH04113832A (en) * 1990-09-04 1992-04-15 Mitsubishi Rayon Co Ltd Structure of honeycomb core
JP3136310B2 (en) 1992-02-26 2001-02-19 東洋カプセル株式会社 Carriers suitable for chewing clothing
US5549204A (en) * 1992-02-26 1996-08-27 Toren Consulting Pty. Ltd. Blister packs
FR2716624B1 (en) 1994-02-25 1996-05-03 Jouveinal Lab Low calorie laxative jelly based on liquid paraffin oil and lactulose, its preparation process.
JP2974204B2 (en) * 1996-02-20 1999-11-10 日本合成化学工業株式会社 Jelly-like candy containing γ-linolenic acid and method for producing the same
JPH1156315A (en) 1997-08-22 1999-03-02 Nippon Synthetic Chem Ind Co Ltd:The Gamma-linolenic acid-containing drink
JPH1156245A (en) * 1997-08-22 1999-03-02 Nippon Synthetic Chem Ind Co Ltd:The Jelly candy containing oil and fat and its production
US6270790B1 (en) 1998-08-18 2001-08-07 Mxneil-Ppc, Inc. Soft, convex shaped chewable tablets having reduced friability
JP2000279107A (en) 1999-03-30 2000-10-10 Lion Corp Noncariogenic easy deglutition composition and food composition and medical composition using the same
PT1244472E (en) * 1999-12-23 2005-09-30 Adisseo France Sas VITAMINIC COMPOSITION IN PARTICLES
DK1320356T4 (en) 2000-09-20 2011-09-12 Nycomed Pharma As Preparation of vitamin emulsions and concentrates thereof
GB0101198D0 (en) * 2001-01-17 2001-02-28 Scherer Technologies Inc R P Ingestible compositions containing an odoriferous oil
US7097868B2 (en) 2001-08-23 2006-08-29 Bio-Dar Ltd. Stable coated microcapsules
US20040001873A1 (en) * 2002-07-01 2004-01-01 Base Marvin Dimitrios Gelled delivery vehicle containing nutritional ingredients
JP2004238419A (en) 2003-02-03 2004-08-26 Bridgestone Corp Adhesive rubber composition
CA2561316A1 (en) * 2004-04-21 2005-11-10 E.I. Du Pont De Nemours And Company Encapsulation of oils by coacervation
US8075910B2 (en) 2004-05-20 2011-12-13 Pbm Pharmaceuticals, Inc. Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
CA2577345C (en) * 2004-08-18 2013-02-19 Hiroki Ueshima Jelly composition
KR100720638B1 (en) 2004-10-22 2007-05-21 액세스 비지니스 그룹 인터내셔날 엘엘씨 Omega-3 Food Product and Related Method of Manufacture
GB0601498D0 (en) 2006-01-25 2006-03-08 Probio Nutraceuticals As Product
JP5238954B2 (en) 2008-02-29 2013-07-17 株式会社大一商会 Game machine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764383A (en) * 1985-10-21 1988-08-16 Michael Drebot Soft homogenous fish bait
EP0474261A2 (en) * 1987-11-25 1992-03-11 Meiji Seika Kaisha Ltd. Production of gelatin jelly confections
WO2003053159A1 (en) * 2001-12-20 2003-07-03 Societe Des Produits Nestle S.A. A food product containing gel capsules or tablets
WO2004054539A1 (en) * 2002-12-16 2004-07-01 The Boots Company Plc Medicinal compositions comprising a core and a film based on modified cellulose derivatives

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3090729B1 (en) 2006-01-25 2023-06-07 Vitux Group AS Emulsion
EP3311801A3 (en) * 2008-10-08 2018-07-25 Vitux Group AS Chewable gelled emulsions
US10668013B2 (en) 2008-10-08 2020-06-02 Vitux Group As Chewable gelled emulsions
US20110268770A1 (en) * 2008-10-08 2011-11-03 Probio Asa Chewable gelled emulsions
WO2010041015A3 (en) * 2008-10-08 2010-09-10 Ayanda As Chewable gelled emulsions
US20170296467A1 (en) * 2008-10-08 2017-10-19 Vitux Group As Chewable gelled emulsions
WO2010041017A2 (en) * 2008-10-08 2010-04-15 Ayanda As Chewable gelled emulsions
WO2010041017A3 (en) * 2008-10-08 2010-06-03 Ayanda As Chewable gelled emulsions
US20110268771A1 (en) * 2008-10-08 2011-11-03 Probio Asa Chewable gelled emulsions
JP2012505190A (en) * 2008-10-08 2012-03-01 プロバイオ エーエスエー Chewable gelled emulsion
US9724296B2 (en) 2008-10-08 2017-08-08 Vitux Group As Chewable gelled emulsions
EP2952176A1 (en) * 2008-10-08 2015-12-09 Ayanda Group AS Chewable gelled emulsions
WO2010041015A2 (en) * 2008-10-08 2010-04-15 Ayanda As Chewable gelled emulsions
US20150037438A1 (en) * 2008-10-08 2015-02-05 Tore Seternes Chewable gelled emulsions
US8187583B2 (en) 2009-01-30 2012-05-29 Conopco, Inc. Oil-in-water emulsions
WO2010086235A1 (en) * 2009-01-30 2010-08-05 Unilever Plc Oil-in-water emulsions
WO2011048388A3 (en) * 2009-10-22 2011-06-30 Probio Asa Oral pharmaceutical and nutraceutical compositions
WO2011128626A1 (en) 2010-04-14 2011-10-20 Probio Asa Essential fatty acid gelled composition
EA025058B1 (en) * 2010-04-14 2016-11-30 Айанда Груп Ас Oral veterinary composition, use thereof in treatment and method of treatment by administration thereof
WO2011128635A2 (en) 2010-04-14 2011-10-20 Probio Asa Anti-abuse pharmaceutical compositions
WO2011128634A3 (en) * 2010-04-14 2012-05-03 Probio Asa Over the counter pharmaceutical compositions
WO2011128627A3 (en) * 2010-04-14 2012-05-03 Probio Asa Oral veterinary pharmaceutical and nutraceutical compositions
WO2011128631A3 (en) * 2010-04-14 2012-05-10 Probio Asa Vegetarian oral pharmaceutical and nutraceutical compositions
WO2011128629A3 (en) * 2010-04-14 2012-05-18 Probio Asa Lipid-vectored drug compositions
WO2011128625A3 (en) * 2010-04-14 2012-05-18 Probio Asa Divisible oral pharmaceutical compositions
WO2011128629A2 (en) 2010-04-14 2011-10-20 Probio Asa Lipid-vectored drug compositions
US10966926B2 (en) 2010-04-14 2021-04-06 Vitux Group As Oral pharmaceutical dispersion compositions
US20130274280A1 (en) * 2010-04-14 2013-10-17 Ayanda Group As Anti-abuse gelled pharmaceutical compositions
WO2011128633A2 (en) 2010-04-14 2011-10-20 Probio Asa Oral pharmaceutical dispersion compositions
WO2011128631A2 (en) 2010-04-14 2011-10-20 Probio Asa Vegetarian oral pharmaceutical and nutraceutical compositions
WO2011128627A2 (en) 2010-04-14 2011-10-20 Probio Asa Oral veterinary pharmaceutical and nutraceutical compositions
WO2011128630A2 (en) 2010-04-14 2011-10-20 Probio Asa Anti-abuse gelled pharmaceutical compositions
WO2011128634A2 (en) 2010-04-14 2011-10-20 Probio Asa Over the counter pharmaceutical compositions
EA025058B8 (en) * 2010-04-14 2017-02-28 Айанда Груп Ас Oral veterinary composition, use thereof in treatment and method of treatment by administration thereof
EP3138553A1 (en) * 2010-04-14 2017-03-08 Ayanda Group AS Oral veterinary pharmaceutical and nutraceutical compositions
WO2011128628A2 (en) 2010-04-14 2011-10-20 Probio Asa Gelled oral pharmaceutical compositions
WO2011128632A2 (en) 2010-04-14 2011-10-20 Probio Asa Gelled pharmaceutical composition
WO2012046066A1 (en) 2010-10-06 2012-04-12 Probio Asa Sour gelled emulsions
EP3178470A1 (en) 2011-04-11 2017-06-14 Vitux Group AS Oral pharmaceutical dispersion compositions
WO2012140392A1 (en) 2011-04-11 2012-10-18 Ayanda Group As Oral pharmaceutical dispersion compositions
US9452135B2 (en) 2012-03-20 2016-09-27 Particle Dynamics International, Llc Gelling agent-based dosage form
EP2934422A4 (en) * 2012-12-23 2016-07-20 Vadim Zelikman A gellan gum carrier for a medicament, means and method
US10532060B2 (en) 2014-03-03 2020-01-14 Raisio Nutrition Ltd. Serum cholesterol lowering edible product
WO2017139846A1 (en) * 2016-02-16 2017-08-24 Atp Institute Pty Ltd Formulation and method of use
EP3511010A4 (en) * 2016-09-09 2020-05-13 TCI Co., Ltd. Fish odor-free fish oil composition and preparation method therefor
GB2597773A (en) * 2020-08-05 2022-02-09 Freddy Hirsch Group Ag Upgrade of animal fats
WO2022029242A1 (en) * 2020-08-05 2022-02-10 Freddy Hirsch Group Ag Upgrade of animal fats
WO2023161658A1 (en) 2022-02-28 2023-08-31 Vitux Group As Oil-in-water emulsion with agar and diacetyl tartaric acid esters of mono-and di-glycerides (datem)

Also Published As

Publication number Publication date
JP5809175B2 (en) 2015-11-10
US9539205B2 (en) 2017-01-10
US20090238866A1 (en) 2009-09-24
AU2007209133B2 (en) 2013-02-21
CA2640069C (en) 2016-06-21
PL3090729T3 (en) 2023-10-30
CA2640529C (en) 2015-04-14
JP2009524633A (en) 2009-07-02
AU2007209128A1 (en) 2007-08-02
CA2640069A1 (en) 2007-08-02
PL1978929T3 (en) 2017-04-28
NO345300B1 (en) 2020-12-07
US20190290580A1 (en) 2019-09-26
EA200801602A1 (en) 2009-02-27
CN101384252B (en) 2013-01-02
EA200801603A1 (en) 2008-12-30
HRP20161720T1 (en) 2017-02-24
EA019116B1 (en) 2014-01-30
EP3090729A1 (en) 2016-11-09
ES2623703T3 (en) 2017-07-12
CN104013567A (en) 2014-09-03
AU2007209133A1 (en) 2007-08-02
JP5295781B2 (en) 2013-09-18
EP1978929B1 (en) 2016-11-23
WO2007085835A1 (en) 2007-08-02
NO20083344L (en) 2008-10-09
PT1978929T (en) 2016-12-27
CA2640529A1 (en) 2007-08-02
US20170071854A1 (en) 2017-03-16
NO342508B1 (en) 2018-06-04
EA014337B1 (en) 2010-10-29
CN101389310A (en) 2009-03-18
DK1978929T3 (en) 2017-01-16
ES2609086T3 (en) 2017-04-18
NO20083340L (en) 2008-10-09
JP2013100317A (en) 2013-05-23
EP3090729B1 (en) 2023-06-07
EP1978943B1 (en) 2017-01-25
GB0601498D0 (en) 2006-03-08
EP1978929A1 (en) 2008-10-15
PL1978943T3 (en) 2017-05-31
ES2952393T3 (en) 2023-10-31
JP5339920B2 (en) 2013-11-13
JP2009526760A (en) 2009-07-23
CN101389310B (en) 2014-06-25
US11123288B2 (en) 2021-09-21
US10383818B2 (en) 2019-08-20
NO342489B1 (en) 2018-06-04
US20090220576A1 (en) 2009-09-03
CN101384252A (en) 2009-03-11
EP1978943A1 (en) 2008-10-15
AU2007209128B2 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
US11123288B2 (en) Emulsion
EP2624814A1 (en) Sour gelled emulsions
AU2013200484B2 (en) Emulsion

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2640069

Country of ref document: CA

Ref document number: 2007209133

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2007705032

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008551874

Country of ref document: JP

Ref document number: 2007705032

Country of ref document: EP

Ref document number: 200801602

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 6974/DELNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007209133

Country of ref document: AU

Date of ref document: 20070125

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200780006284.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2007209133

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12162339

Country of ref document: US